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Introduction: The purpose of this study was to compare patterns of 
failure between lobar resection (lobectomy or pneumonectomy) and 
stereotactic body radiation therapy (SBRT) for patients with clinical 
stage I non–small-cell lung cancer (NSCLC).
Methods: From January 2004 to January 2008, 338 patients under-
went definitive treatment for pathologically confirmed clinical stage 
I NSCLC with lobar resection (n = 260) or SBRT (n = 78). Most 
surgical patients underwent lobectomy (n = 237). SBRT patients 
received a biologically effective dose of at least 100 Gy
10
. Lobar 
resection patients were younger, healthier, and had superior pulmo-
nary function, whereas most of the patients in the SBRT group had 
T1 tumors. Final pathology upstaged 32.7% of surgery patients, and 
20.0% received adjuvant chemotherapy. No SBRT patients received 
adjuvant chemotherapy.
Results: In an unmatched comparison, 4-year lobar local control (98.7% 
versus 93.6%, p = 0.015) was greater for lobar resection versus SBRT, 
respectively, though primary tumor (98.7% versus 95.3%, p = 0.088), 
regional (82.9% versus 78.1%, p = 0.912), and distant control (76.1% 
versus 54.0%, p = 0.152) were similar. Overall survival (OS, 63.5% ver-
sus 29.6%, p < 0.0001) was greater for lobar resection, though cause-
specific survival (CSS, 81.3% versus 75.3%, p = 0.923) was similar. In 
a T-stage matched comparison of 152 patients, there was no significant 
difference in patterns of failure or CSS, whereas OS favored surgery.
Conclusion: Lobectomy/pneumonectomy or SBRT results in com-
parable patterns of failure for clinical stage I NSCLC. In this retro-
spective comparison, OS was superior for surgery, though CSS was 
similar. Randomized trials are necessary to control for fundamen-
tal differences in comorbidity, which impact interpretation of both 
tumor control and survival.
(J Thorac Oncol. 2013;8: 192–201)
For patients with medically operable clinical stage I non–small-cell lung cancer (NSCLC), lobectomy or pneu-
monectomy results in primary tumor control approaching 
100% and 5-year overall survival of 53% and 43% for 
tumors 2 cm or more and 2.1 to 5 cm, respectively.1,2 Patients 
at higher risk of surgery may be offered sublobar resection 
with acceptable morbidity and mortality.3 Sublobar resec-
tion with a nonanatomical wedge resection results in sig-
nificantly higher local failure relative to lobar resection,4 
though this may be improved through the use of brachyther-
apy,5 careful intraoperative margin assessment,6 or anatomi-
cal segmentectomy.7 For patients with medically inoperable 
stage I NSCLC, stereotactic body radiotherapy (SBRT) 
has become a standard of care based on high rates of local 
control, convenience, cost, and survival relative to historic 
outcomes after conventional radiotherapy, with low rates of 
toxicity.8–11 As experience with SBRT has grown, improved 
local control and survival after SBRT has been shown to 
correlate with biologically effective doses (BED) of radia-
tion greater than 100 Gy
10
.12,13
SBRT in medically operable patients was reported first 
from Japan, where high 3-year rates of local control (94%) and 
overall survival (86%) were documented in patients refusing 
surgery.14 No randomized trials comparing surgery and SBRT 
have been completed to date. The ROSEL (Radiosurgery Or 
Surgery for operable Early stage non-small cell Lung cancer) 
trial opened in Holland and attempted to compare lobectomy 
versus SBRT in stage I NSCLC, though it failed to reach its 
accrual goal and was closed. The STARS (Randomized Study 
to Compare CyberKnife Stereotactic Radiotherapy With 
Surgical Resection in Stage I Non-small Cell Lung Cancer) 
trial (sponsored by Accuray, Inc., Sunnyvale, CA) exclusively 
compares CyberKnife SBRT with lobectomy. American 
College of Surgeons Oncology Group (ACOSOG) Z4099 
and Radiation Therapy Oncology Group (RTOG) 1021 is a 
National Cancer Institute trial, which randomizes patients at 
high risk for surgery to either sublobar resection (± brachy-
therapy) or SBRT.
Retrospective comparisons between surgery and SBRT 
to date have been limited and suffer from inherent imbalances 
in the treatment arms, with healthier patients being selected 
for surgery.14–19 Two recent publications directly comparing 
surgery and SBRT have addressed this by narrowing the focus 
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to only high-risk patients.16,17 Such comparisons have been 
criticized for having different definitions for failure between 
surgery and SBRT.20 No publications to date have compared 
outcomes specifically between lobar resection and SBRT. The 
purpose of this study is to compare institutional outcomes 
between definitive standard lobar resection and optimally 
dosed SBRT (BED > 100 Gy
10
) using a uniform definition of 
failure. Given the inherent difficulty in comparing survival 
for groups of patients selected for therapy based on medical 
comorbidity, we focus primarily on patterns of failure.
MATERIALS AND METHODS
From January 2004 to January 2008, 454 patients (336 
surgery, 118 SBRT) were identified with clinical stage I lung 
cancer from Institutional Review Board–approved patient 
registries located in the departments of Cardiothoracic 
Surgery and Radiation Oncology at Washington University in 
St. Louis, Missouri. Selection of patients with clinical stage 
I NSCLC was based on the American Joint Committee on 
Cancer (AJCC) 6th edition staging manual,21 and was ret-
rospectively coded using the 7th edition for the study.22 The 
data set was narrowed to include only patients (1) undergoing 
anatomical lobar resection (lobectomy or pneumonectomy) 
or SBRT to a BED of 100 Gy
10
 or more and (2) having patho-
logic confirmation of NSCLC. Details of inclusion or exclu-
sion resulting in the final study group are described in the 
Figure 1.
Standard work-up for all patients included history and 
physical examination, computed tomography (CT) of the chest 
and abdomen, and [18F] fluorodeoxyglucose (FDG)–positron 
emission tomography (PET) CT. PET or CT was performed in 
100% of surgery patients and 98.7% (n = 77) SBRT patients. 
Patients were selected for lobar resection if they were con-
sidered by the thoracic surgeon to have adequate pulmonary 
function to tolerate at least a lobectomy and absence of other 
contraindicating medical comorbidity. Patients were selected 
for SBRT if they were considered to be medically inoperable 
by the thoracic surgeon, or if they were felt to be at high risk 
for surgery, and declined sublobar resection after a balanced 
discussion with the surgeon and radiation oncologist.
Baseline patient, tumor, and treatment variables are sum-
marized in Table 1. Medical comorbidity was assessed by the 
Adult CoMorbidity Evaluation (ACE-27) scoring system and 
Charlson Comorbidity Index (CCI), both of which have been 
validated in patients with lung cancer.23,24 The ACE-27 score 
was collected prospectively during a patient’s registration at 
the Siteman Cancer Center. The CCI and an age-adjusted CCI 
(AA-CCI) were scored retrospectively.25
For patients treated with lobar resection, the type of 
resection, type of incision, and extent of lymph node dis-
section were at the discretion of the treating surgeon. Most 
patients underwent lobectomy, with the rest undergoing 
bilobectomy or pneumonectomy. Surgery was through open 
thoracotomy in 224 patients and video-assisted thoraco-
scopic surgery in 36 patients. Institutional policy dictated 
that patients undergo mediastinoscopy before thoracotomy 
(either in advance of surgery, or at the time of surgery), fol-
lowed by formal lymph node dissection at the time of lobec-
tomy. Pathologic upstaging occurred in 85 patients (32.7%) 
undergoing surgery, of which tumor stage was higher in 51 
cases (19.6%), and occult nodal disease was discovered in 
56 cases (21.5%). For nodal stage, 43 patients were found 
to have pathologic N1 disease and 13 patients had N2 dis-
ease. For tumor stage, 46 patients were upstaged from T1 (36 
T2, 3 T3, and 7 T4) and five patients were upstaged from T2 
(4 T3, 1 T4). In addition, 10 patients (3.8%) had downstag-
ing from T2 to T1 tumors. Fifty-two patients (20.0%) treated 
with lobar resection received adjuvant chemotherapy, and 20 
(7.7%) received adjuvant radiotherapy.
Details of SBRT planning and delivery at our institution 
have been described previously.26 Target coverage, conformal-
ity, and normal tissue constraints were followed according to 
RTOG 0236.8 Prescriptions were typically specified at the 60% 
to 90% (median 84%) isodose line so that 95% or more of the 
prescribed dose covered the planning target volume. All SBRT 
patients received a BED of at least 100 Gy
10
 (median dose, 54 
Gy in 3 fractions). BED was calculated using BEDα/β = nd(1+ 
d/α/β), where n = number of fractions, d = dose per frac-
tion, and α/β = 10 for tumor in line with previous reports.13,27 
BED
10
 for the three SBRT regimens used in this study was 151 
Gy, 100 Gy, and 113 Gy for 54 Gy/3 fractions (fx), 50 Gy/5 
fx, and 45 Gy/3 fx, respectively. No SBRT patients received 
adjuvant chemotherapy.
Patients were followed with serial chest radiographs 
and/or CT scans every 3 months for the first 2 years, every 
6 months thereafter up to 5 years, and yearly afterward. A 
PET/CT was performed if there was suspicion for recurrence. 
Failures were defined using a combination of enlargement 
on CT and increasing [18F]FDG avidity on PET/CT, with 
biopsy confirmation when feasible. To eliminate historic 
discrepancies in definitions of failure between surgery and 
SBRT, tumor control was defined in the spirit of ACOSOG 
Z4099/RTOG 1021.28 Local failure was defined for SBRT as FIGURE 1.  Details of inclusion and exclusion.
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TABLE 1.  Patient Characteristics, Unmatched Comparison between SBRT and Lobar Resection
Characteristic SBRT (n=78) Lobar Resection (n=260) p
Age, yrs
 Median (range) 76 (31–93) 66 (40–87) <0.0001
Sex, n (%)
 Women 34 (43.6) 120 (46.2) 0.700
Race, n (%) 0.530
 White 68 (87.2) 234 (90.0)
 Black 10 (13.2) 21 (8.1)
 Others 0 (0) 5 (1.9)
Smokers, n (%) 75 (96.2) 244 (93.9) 0.581
 Prior NSCLC, n (%) 15 (19.2) 19 (7.3) 0.002
ACE-27 Comorbidity Index
 Median (range) 2 (0–3) 1 (0–3) <0.0001
Charlson Comorbidity Index
 Median (range) 4 (2–10) 3 (2–22) <0.0001
Age-adjusted Charlson Comorbidity Index
 Median (range) 7 (3–12) 6 (2–28) 0.0048
FEV1, L
 Median (range) 1.31 (0.38–2.89) 2.03 (0.82–5.58) <0.0001
FEV1, % predicted
 Median (range) 51 (20–133) 80 (26–138) <0.0001
FVC, L
 Median (range) 2.2 (0.69–3.47) 3.05 (1.42–6.92) <0.0001
FVC, % predicted
 Median (range) 79 (33–129) 90 (38–184) 0.001
DLCO, ml/min/mm Hg
 Median (range) 11 (6.28–33) 16 (1.04–40.07) 0.002
DLCO, % predicted
 Median (range) 63 (23–114) 72 (12–190) 0.003
Histology, %
 Adenocarcinoma 36 (46.2) 154 (59.2) 0.026
 Squamous cell carcinoma 25 (32.1) 88 (33.9)
 NSCLC, not otherwise specified 16 (20.5) 8 (3.1)
 Other/unknown 1 (1.3) 10 (3.8)
Maximal axial CT dimension, cm
 Median (range) 2 (1.1–6) 2.8 (0.7–12.8) 0.001
AJCC 6th edition stage, n (%)
 T1 56 (71.8) 141 (54.2) 0.006
 T2 22 (28.2) 119 (45.8)
AJCC 7th edition stage, n (%)
 T1a 36 (46.2) 83 (31.9) 0.010
 T1b 20 (25.6) 56 (21.5)
 T2a 19 (24.4) 83 (31.9)
 T2b 3 (3.8) 23 (8.9)
 T3 0 (0) 15 (5.8)
F18-FDG SUVmax primary
 Median (range) 5 (0.9–18.5) 4.8 (1–25.2) 0.893
SBRT dose, n (%)
 54 Gy/3 fx 68 (87.2) N/A
 50 Gy/5 fx 4 (5.1)
 45 Gy/3 fx 6 (7.7)
Surgery, n (%)
 Lobectomy 237 (91.2) N/A
 Bilobectomy 8 (3.1)
 Pneumonectomy 15 (5.8)
Not all percentages add up to exactly 100%, secondary to rounding.
NSCLC, non–small-cell lung cancer; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; 
CT, computed tomography; AJCC, American Joint Committee on Cancer; ACE, Adult CoMorbidity Evaluation; F18-FDG, fluorodeoxyglucose; SUV, standard uptake value; SBRT, 
stereotactic body radiation therapy; fx, fraction.
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progression in the region of the primary tumor or the involved 
lobe, and for surgery as failure at the bronchial stump or port 
site/wound. Primary tumor failure was defined for SBRT 
as progression in the region of the primary tumor alone. 
Regional failure was defined as failure in hilar or mediastinal 
lymph nodes, and distant metastases were defined as failures 
outside of local or regional failures. Toxicity was coded using 
Common Terminology Criteria for Adverse Events version 
4 for SBRT patients, and toxicities were described but not 
graded for lobar resection.
Median follow-up was calculated using the Kaplan–
Meier estimated potential follow-up method.29 Differences 
between treatment groups were described using a two-tailed 
t test for means, Wilcoxon rank sum for medians, and χ2 test 
for proportions. Univariate analysis of factors was performed 
using Cox regression for continuous variables and log-rank 
for categorical variables. Assumptions of the Cox model were 
checked. Multivariate analysis was performed using the Cox 
proportional hazards model. SBRT and lobar resection were 
compared with regard to local control (LC), primary tumor 
control (PC), regional control (RC), distant control (DC), 
overall survival (OS), and cancer-specific survival (CSS), 
using the Kaplan–Meier method. For representative time 
points, standard errors were reported. An attempt was made 
to match subgroups of patients treated with lobar resection or 
SBRT on select covariates, using a propensity-score matching 
(PSM) technique. For PSM, logistic regression is first used to 
estimate propensity scores from baseline patient covariates, 
after which patients are matched on their propensity scores. 
Matching was accomplished using a caliper method, whereby 
treatment groups are randomly sorted, and patients were ran-
domly matched within an acceptable distance (caliper) of pro-
pensity scores. We previously identified a caliper parameter 
of 0.005 as providing an acceptable balance between strin-
gency (i.e., closer matches) and patient numbers.17 For the 
PSM-matched patients, stratified log-rank tests were used for 
Kaplan–Meier comparisons.
RESULTS
Median follow-up was 51.3 months for surgery and 50.3 
months for SBRT. Patients treated with lobar resection were 
significantly younger, healthier, and had superior pulmonary 
function compared with the SBRT group. A greater propor-
tion of tumors in the SBRT group were clinical T1. SBRT 
patients had more than double the incidence of previously 
treated lung cancer. Median time from prior cancer to current 
cancer for SBRT and surgery was 3.2 years (range, 0.6–19.2) 
and 5.3 years (range, 2.0–11.7), respectively. Kaplan–Meier 
plots comparing patterns of failure and survival for the entire 
cohort of patients are presented in Figure 2. Local failures in 
both groups were uncommon. In the lobar resection group, 
one patient developed a bronchial stump failure and one addi-
tional patient developed a port site failure. In the SBRT group, 
two patients developed primary tumor failure and one addi-
tional patient developed a failure in the same lobe outside of 
the primary. Limited events notwithstanding, 4-year LC was 
higher for lobar resection versus SBRT (98.7%±0.9% versus 
93.6%±3.6%, p = 0.015), though PC was not significantly 
different (98.7%±0.9% versus 95.3%±4.7%, p = 0.088). No 
significant difference was seen in 4-year RC (82.9%±2.7% 
versus 78.1%±7.3%, p = 0.912) or DC (76.1%±3.0% versus 
54.0%±9.8%, p = 0.152) for surgery or SBRT, respectively, 
though a suggestive trend toward worse DC was seen for 
SBRT after 3 years. OS (63.5%±3.2% versus 29.6%±5.9%, p 
< 0.0001) was greater for patients treated with lobar resection, 
though CSS (81.3%±2.7% versus 75.3%±6.8%, p = 0.923) 
was similar.
Univariate analysis was used on all baseline covariates, 
listed in Table 1, to determine their impact on patterns of fail-
ure and survival. Only those covariates found to be significant 
on univariate analysis were submitted for multivariate analy-
sis. In the event that less than two covariates were significant 
on univariate analysis for a given outcome, no multivariate 
analysis was performed (N/A). A summary of factors found to 
be significant or approaching significance are listed in Table 2.
Propensity Score Matching
Given the difference in OS and suggestive difference 
in late DC between the treatment groups, we reviewed the 
list of covariates found to be predictive of these outcomes on 
univariate and multivariate analysis as potential variables for 
PSM. Patient selection for therapy at our institution was driven 
by medical comorbidity and confirmed by an overwhelming 
weighting of covariates, predictive of improved OS in favor of 
lobar resection (Table 1). With increasing numbers of covari-
ates to match upon, PSM returns very small patient numbers. 
As such, PSM was not attempted for OS. In contrast, only AJCC 
7th edition clinical T-stage was predictive of DC. Therefore, we 
performed PSM using T-stage in an attempt to determine the 
impact this might have on the suggestive split in DC.
Seventy-six patients from each treatment group were 
identified using PSM for AJCC 7th edition clinical T-stage. 
As shown in Table 3, PSM successfully matched the two treat-
ment groups with regard to AJCC 7th edition stage (p = 0.706) 
as well as AJCC 6th edition stage (p = 0.794) and maximal 
axial tumor size on CT (p = 0.794). After matching, median 
tumor size for both groups was 2 cm, eliminating patients 
with larger tumor sizes in the lobar resection group. Despite 
matching for stage, patients treated with SBRT remained 
with a significantly higher burden of risk factors predictive of 
poorer OS.
Kaplan–Meier plots comparing patterns of failure 
and survival for the stage-matched cohort are presented in 
Figure 3. In the T-stage-matched cohort, no significant differ-
ences in 4-year LC (98.5%±1.5% versus 93.5%±3.7%, p = 
0.222), PC (98.5% ±1.5% versus 95.2%±3.3%, p = 0.434), 
RC (77.8%±5.7% versus 82.9%±5.8%, p = 0.454), or DC 
(72.3%±6.0% versus 57.0%±9.7%, p = 0.420) were appar-
ent between lobar resection and SBRT, respectively. The 
suggestive improvement in DC in favor of surgery was lost 
after matching for stage. As before, OS (57.9%±6.3% versus 
29.3%±5.9%, p = 0.0007) was significantly higher for patients 
treated with lobar resection whereas CSS (77.3%±.5% versus 
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FIGURE 2.  Kaplan–Meier curves for local control, primary tumor control, regional control, distant control, overall survival, and 
cancer-specific survival between the entire cohort of patients treated with lobar resection or SBRT. SBRT, stereotactic body radia-
tion therapy.
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74.7%±6.9%, p = 0.898) remained similar for lobar resection 
and SBRT.
Toxicity
Overall patterns and degrees of toxicity were different 
between the two treatment groups, and were not comparable 
statistically. For patients treated with SBRT, acute toxic-
ity consisted of two patients with esophagitis (one grade 1, 
one grade 2). Late toxicities after SBRT included six patients 
(7.7%) with grade 2 or more pneumonitis (5 grade 2, 1 grade 
3), and one each of a grade 1 brachial plexopathy, a grade 
2 pleural effusion, and a grade 3 soft-tissue necrosis. Fifteen 
patients (19.2%) developed chest-wall pain after SBRT (10 
grade 1, 4 grade 2, 2 grade 3). No deaths were attributed to 
SBRT.
Thirty-day postoperative mortality was 1.5% (n = 
4) for patients treated with lobar resection. One additional 
patient died at 3 months, after a prolonged stay in the inten-
sive care unit because of respiratory failure after surgery, 
for a total conservative operative mortality of 1.9% (n = 5). 
Cardiovascular complications after surgery included atrial 
fibrillation in 28 patients (10.8%), other arrhythmia in three 
patients, myocardial infarction in five patients, and a stroke in 
one patient. Pulmonary complications included new require-
ments for supplemental oxygen in 18 (6.9%), pneumonia/
respiratory failure in 15 (5.8%), prolonged air leak in 11, 
vocal cord paralysis in four, and tracheostomy placement 
in two patients, respectively. Bleeding requiring additional 
surgery occurred in seven patients (5 hemothorax, 2 wound 
hematoma).
DISCUSSION
Our intent was to compare patterns of failure between 
lobectomy or pneumonectomy and SBRT using a coherent 
definition of failure in both groups. These results demon-
strate that patterns of failure between optimal surgery (lobar 
resection) and optimally dosed SBRT (BED
10
 > 100 Gy) are 
similar. However, our results also highlight the difficulties in 
making such comparisons, given the inherent imbalance in 
both patient and tumor-related factors.
It is heartening to note that both treatments produced 
high rates of LC and PC. However, the limited number of total 
events makes direct comparisons difficult and also hinders 
the ability to identify factors predictive of local failure. For 
example, although tumor size (by stage or CT size) was not 
predictive of LC or PC on Cox regression, size is certainly a 
well-accepted predictor for increased risk of local failure after 
either treatment. Delayed failures may happen for both modal-
ities. One of the local failures for surgery occurred more than 
3 years after surgery. Delayed failures have also been reported 
TABLE 2.  Univariate and Multivariate Analysis of Factors Correlating with Patterns of Failure and Survival  
for the Entire Cohort
Outcome UVA HRa (95% CI) p MVA HR (95% CI) p
LC Treat (SBRT vs. surgery) 7.14 (1.14–41.9) 0.035 N/A
PC NONE N/A
RC CT size 1.14 (0.98–1.32) 0.081 N/A
DC Stage (7th AJCC edition, T2a vs. T1a) 2.40 (1.26–4.58) 0.008 N/Ab
Stage (7th AJCC edition, T1b vs. T1a) 2.59 (1.33–5.04) 0.005
Histology (nonsquam vs. squam) 1.66 (0.94–2.94) 0.081
OS Treat (SBRT vs. surgery) 2.43 (1.74–3.39) <0.0001 Treat (SBRT 
vs. surgery)
1.65 (1.03–2.67) 0.039
ACE-27 (2–3 vs. 0–1) 1.64 (1.20–2.25) 0.002 CCI 1.17 (1.01–1.35) 0.036
CCI 1.14 (1.07–1.21) <0.0001 Age 1.03 (1.01–1.05) 0.005
CCIa 1.11 (1.06–1.16) <0.0001
Sex (male vs. female) 1.52 (1.11–2.10) 0.011
Age 1.04 (1.02–1.06) <0.0001
FEV1 1.31 (1.01–1.68) 0.039
FEV1 % 1.01 (1.00–1.02) 0.015
CSS Stage (6th AJCC edition, ≥T2 vs. T1) 1.66 (0.99–2.80) 0.055 CT size 1.18 (1.02–1.36) 0.026
Stage (7th AJCC edition, T2a vs. T1a) 2.57(1.25–5.28) 0.010 DLCO % 1.01 (1.00–1.03) 0.047
Stage (7th AJCC edition, T1b vs. T1a) 2.20 (1.02–4.73) 0.045
CT size 1.16 (1.03–1.31) 0.017
DLCO % 1.01 (1.00–1.03) 0.026
aHazard ratios more than 1 indicate an increased risk of failure for each outcome. For categorical variables, the comparison variable is listed in parentheses. For continuous variables, 
larger values are correlated with an increased risk of failure for each outcome. Outcomes in italics approached, but did not reach, statistical significance.
bStage (7th edition) is a single variable, despite being reported as individual comparisons for UVA to report a HR. As stage (7th edition) was the only variable significant for DC 
on UVA, MVA was not performed.
N/A, not applicable; LC, local control; PC, primary tumor control; RC, regional control; DC, distant control; OS, overall survival; CSS, cancer-specific survival; UVA, univariate 
analysis; MVA, multivariate analysis; HR, hazard ratio; 95% CI, 95% confidence interval; CT, computed tomography; CT size, maximal axial CT dimension; DLCO, diffusing capacity 
of the lung for carbon monoxide; Treat, treatment; squam, squamous histology; nonsquam, nonsquamous histology; AJCC, American Joint Committee on Cancer; CCI, Charlson 
Comorbidity Index; CCIa, age-adjusted CCI.
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TABLE 3.  Patient Characteristics, AJCC 7th Edition Stage-Matched Comparison between SBRT and Lobar 
Resection
Characteristic SBRT (n=76) Lobar Resection 
(n=76)
p
Age, yrs
 Median (range) 76 (31–93) 65 (40–87) <0.0001
Sex, n (%)
 Women 34 (44.7) 39 (51.3) 0.516
Race, n (%) 0.803
 White 66 (86.8) 67 (88.2)
 Black 10 (13.2) 8 (10.5)
 Others 0 1 (1.3)
Smokers, n (%) 73 (96.1) 71 (93.4) 0.719
Prior NSCLC, n (%) 15 (19.7) 6 (7.9) 0.058
ACE-27 Comorbidity Index
 Median (range) 2 (0–3) 1 (0–3) <0.0001
Charlson Comorbidity Index
 Median (range) 4 (2–10) 3 (2–11) <0.0001
Age-adjusted Charlson Comorbidity Index
 Median (range) 7 (3–12) 6 (2–17) 0.004
FEV1, L
 Median (range) 1.31 (0.39–2.58) 2.03 (0.85–4.38) <0.0001
FEV1, % predicted
 Median (range) 51 (20–133) 79 (26–138) <0.0001
FVC, L
 Median (range) 2.2 (0.69–3.47) 3.01 (1.54–5.99) <0.0001
FVC, % predicted
 Median (range) 79 (33–129) 89.5 (40–146) 0.003
DLCO, mL/min/mm Hg
 Median (range) 11 (6.28–33) 16.9 (6.63–40.1) 0.001
DLCO, % predicted
 Median (range) 62 (23–114) 79.0 (35–190) 0.001
Histology, %
 Adenocarcinoma 34 (44.7) 46 (60.5) 0.143
 Squamous cell carcinoma 25 (32.9) 25 (32.9)
 NSCLC, not otherwise specified 16 (21,1) 2 (2.6)
 Other/unknown 1 (1.3) 3 (3.9)
Maximal axial CT dimension, cm
 Median (range) 2 (1.1–6) 2 (0.8–5.8) 0.794
AJCC 6th edition stage, n (%)
 T1 56 (73.7) 59 (77.6) 0.706
 T2 20 (26.3) 17 (22.4)
AJCC 7th edition stage, n (%)
 T1a 36 (47.4) 39 (51.3) 0.914
 T1b 20 (26.3) 20 (26.3)
 T2a 17 (22.4) 15 (19.7)
 T2b 3 (3.9) 2 (2.6)
 T3 0 (0) 0 (0)
F18-FDG SUVmax primary
 Median (range) 5 (0.9–18.5) 3.65 (1.0–23) 0.205
SBRT dose, n (%)
 54 Gy/3 fx 66 (86.8) N/A
 50 Gy/5 fx 4 (5.3)
 45 Gy/3 fx 6 (7.9)
Surgery, n (%)
 Lobectomy 72 (94.7) N/A
 Bilobectomy 2 (2.6)
 Pneumonectomy 2 (2.6)
Not all percentages add up to exactly 100%, secondary to rounding.
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; CT, computed tomography; AJCC, American 
Joint Committee on Cancer; F18-FDG, fluorodeoxyglucose; SUV, standard uptake value; SBRT, stereotactic body radiation therapy; SUV, ; NSCLC,non–small-cell lung cancer; 
ACE, Adult Comorbidity Evaluation; fx, fraction.
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FIGURE 3.  Kaplan–Meier curves for local control, primary tumor control, regional control, distant control, overall survival, 
and cancer-specific survival between AJCC 7th edition stage-matched patients treated with lobar resection and SBRT. AJCC, 
American Joint Committee on Cancer; SBRT, stereotactic body radiation therapy.
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after SBRT.30 Given the limited number of patients alive in 
either group at later time points, long-term control should be 
interpreted with caution.
Occult nodal disease was discovered in more than 20% 
of patients undergoing lobar resection. We did not find a dif-
ference in RC between surgery and SBRT, which is in line with 
most previous reports detailing regional failure after SBRT.8 
Several theories have been postulated to explain the lower 
than expected regional failure for clinically staged patients 
treated with SBRT, including scatter radiation to the nodes and 
a tumor vaccination phenomenon.16,31 Nevertheless, if a simi-
lar proportion of patients in the SBRT group has microscopic 
nodal metastases, this should translate into an increased risk 
for distant metastases in a population of patients who receive 
no adjuvant chemotherapy.
Though DC was not statistically different between the 
two treatments in an unmatched comparison, there was a sug-
gestive split in favor of surgery after 3 years. After match-
ing for T-stage, this difference became less apparent. Possible 
explanations for the difference between overall- and stage-
matched cohorts include history of prior lung cancers, tumor 
size, nodal dissection, and use of adjuvant chemotherapy. 
Patients treated with SBRT had more than double the inci-
dence of prior lung cancers, and it is certainly possible that 
some of these patients treated for presumed metachronous 
cancers in fact had early metastatic disease. Although history 
of prior lung cancer did not correlate with any pattern of fail-
ure outcome on Cox regression, the lack of statistical signifi-
cance does not rule out the possibility of a contribution to the 
suggestive split in DC. In the unmatched comparison, median 
tumor size was larger for lobar resection. Increasing tumor 
size is a well-established predictor of both nodal and subse-
quent distant failure. A logical explanation for the apparent 
improvement in DC for surgery in the unmatched comparison 
is the use of node dissection and subsequent adjuvant chemo-
therapy for node-positive patients. After matching for stage, 
median tumor size between SBRT and lobar resection was 
identical (2 cm), potentially mitigating some of the benefits 
of node dissection and chemotherapy. Given the established 
benefit for adjuvant chemotherapy for node-positive disease, 
this would support the need for a more thorough nodal evalu-
ation in SBRT patients. Selective mediastinoscopy and/or 
minimally invasive staging tools, such as radial endobronchial 
ultrasound and endoscopic ultrasound via esophagoscopy, 
will undoubtably play a more valuable role as the use of SBRT 
expands.32
Nonrandomized comparisons of surgery and SBRT are 
difficult, particularly with regard to OS, as surgical patients 
are by definition healthier. Onishi et al.15 reviewed outcomes 
after SBRT for operable patients with stage I NSCLC across 
14 Japanese institutions. Five-year LC for T1 and T2 tumors 
was 92% and 73%, respectively, and 5-year OS was 72% 
and 62%. Although these outcomes compare favorably to 
similar reports for surgery, no companion surgical group was 
included. Grills et al.16 compared wedge resection to SBRT 
in patients with high-risk stage I NSCLC. A suggestive trend 
towards decreased 30-month local recurrence was noted in 
favor of SBRT (4% versus 20%, p = 0.07), though regional 
(4% versus 18%) and distant recurrence (19% versus 21%) 
was not significantly different. Likewise, CSS was identical at 
94% and 93%, respectively. Despite the suggested improve-
ments in locoregional control with SBRT, OS in the wedge 
group was superior (87% versus 72%, p = 0.01), which was 
felt to reflect the inferior health of SBRT patients.
In an earlier publication, we matched a small number of 
surgery and SBRT patients in an attempt to compare OS.17 In 
this more heterogeneous population, surgical patients under-
went either sublobar or lobar resection and several SBRT 
patients received suboptimal doses (BED
10
 < 100 Gy). In the 
group as a whole, LC, RC, and CSS were similar between 
treatments, whereas OS was superior for surgery. After match-
ing with PSM for age, T-stage, and ACE-27 score, OS was not 
different between the groups. In the current analysis, the supe-
rior OS in the lobar resection group should not be overinter-
preted, given the dramatic differences in comorbidity. Such 
confounding by indication is a well-described consequence of 
such observational studies, which is not readily correctable 
with current adjustment methods.33 It is notable that CSS was 
identical between the treatment groups in both unmatched and 
stage-matched comparisons. Thus, despite having worse OS 
compared with lobar resection, patients treated with SBRT 
died from cancer at the same rate as those undergoing surgery. 
SBRT patients were less healthy and many died of noncancer 
causes. Only randomized comparisons between surgery and 
SBRT will avoid the imbalances and selection biases present 
in this and other nonrandomized comparisons.
In conclusion, this institutional analysis of patients 
with clinical stage I NSCLC reveals comparable patterns of 
failure between lobectomy/pneumonectomy and SBRT, with 
improved LC and a suggestion of improved DC for surgery 
in the unmatched cohort. In a T-stage matched comparison, 
patterns of failure between surgical and SBRT groups were 
identical. Overall survival was superior in the surgical group 
irrespective of matching. These results support the need to 
enroll patients on randomized trials (such as ACOSOG Z4099/
RTOG 1021, STARS).
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